Korea Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Korea Pharma makes prescription medicines, tablets, capsules, liquids, and ointments, covering a broad range of conditions including mental-health disorders, digestive and cardiovascular diseases, infections, diabetes, and respiratory ailments.
Hospitals, clinics, and pharmacies in Korea and overseas markets across Asia, Africa, and the Middle East use its products. Listed on KOSDAQ, Korea's small-cap and technology board, the company runs three distinct business lines: manufacturing and supplying its own branded generics and improved formulations, contract manufacturing (CMO) for other pharmaceutical companies, and direct export of its product range.
Summary is AI-generated and may contain errors · figures from DART filings
The company previously assigned a patent for an oral pharmaceutical composition containing choline alfoscerate to Daewoong Bio Co., Ltd., indicating an established domestic licensing-out track record.
Korea Pharma in five facts
What does Korea Pharma do?
Korea Pharma makes prescription medicines, tablets, capsules, liquids, and ointments, covering a broad range of conditions including mental-health disorders, digestive and cardiovascular diseases, infections, diabetes, and respiratory ailments.
Where is Korea Pharma listed and in which sector?
Korea Pharma (Korean name: 한국파마) trades under KRX code 032300 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Korea Pharma?
Its market capitalisation was US$69M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Korea Pharma's latest annual revenue and operating profit?
For fiscal year 2025, Korea Pharma reported revenue of US$66.1M, an operating loss of US$669.7K and a net loss of US$2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 7.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material event report (treasury share trust agreement)Oct 2
- Early redemption of convertible bonds (incl. overseas CBs)
Korea Pharma acquired the full remaining US$3.62M face value of its Series 4 private-placement convertible bonds on August 28, 2026 following the bondholder's exercise of an early-redemption put option, extinguishing the bonds via cancellation of the registered bond.
Capital raise · Aug 28 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 28
- Material event report (convertible bonds)
Korea Pharma disclosed convertible bonds to raise US$10M, about 16.1% of its market value.
Capital raise · May 20 - Cash/in-kind dividend decision
Korea Pharma declared a cash dividend of US$0.03 per share, equal to about 0.4% of the recent share price.
Dividend · Mar 6 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Korea Pharma reported separate results for FY2025: revenue of US$59.2M (+7.8% year on year), an operating loss of US$600K (from a profit a year earlier) and a net loss of US$1.78M (from a profit a year earlier).
Earnings · Mar 6